UMR 85 Physiology of Reproduction and Behaviour, National Research Institute for Agriculture, Food and Environment (INRAE) Centre Val de Loire, Nouzilly, France.
Department of Reproductive Medicine and Biology, University Hospital of Tours, Tours, France.
J Endocrinol. 2021 Apr;249(1):57-70. doi: 10.1530/JOE-20-0550.
Vaspin is a novel adipokine mainly expressed in visceral adipose tissue and closely related to obesity and insulin-resistance. Currently, data about its ovarian expression are limited to animal models and its role in human reproduction is largely unexplored. Our study's aims were then to characterise vaspin expression in the human ovary and to study in vitro its effects on granulosa cells physiology. Secondly, we assessed vaspin and its receptor GRP78 variations in granulosa cells and follicular fluid of a cohort of 112 infertile women undergoing an in vitro fertilisation procedure and allocated to three groups, each including normal-weight and obese subjects: 34 PCOS patients, 33 women with isolated polycystic ovary morphology (ECHO group) and 45 controls. Vaspin and GRP78 expression in the ovary was assessed by immunohistochemistry, RT-qPCR and Western blot. Granulosa cells and follicular fluid were analysed by RT-qPCR and ELISA, respectively. In vitro, granulosa cells metabolism was studied after stimulation with recombinant human vaspin, with and without a siRNA directed against GRP78. Vaspin was highly expressed in the human ovary and concentration-dependently enhanced granulosa cells steroidogenesis, proliferation and viability through GRP78 (P < 0.0001). Vaspin levels in both granulosa cells and follicular fluid were significantly higher in obese women (P < 0.0001) and in the normal-weight ECHO group (P < 0.001), which also had the highest expression rates of GRP78 (P < 0.05). Although further investigation is needed, vaspin appears as a novel modulator of human granulosa cells physiology and possibly plays a role in PCOS pathogenesis, notably protecting from insulin-resistance induced complications.
脂联素是一种新型脂肪因子,主要在内脏脂肪组织中表达,与肥胖和胰岛素抵抗密切相关。目前,关于其在卵巢中的表达数据仅限于动物模型,其在人类生殖中的作用在很大程度上仍未被探索。因此,我们的研究旨在描述人卵巢中脂联素的表达,并研究其对颗粒细胞生理学的体外作用。其次,我们评估了脂联素及其受体 GRP78 在接受体外受精过程的 112 名不孕妇女的颗粒细胞和卵泡液中的变化,并将其分为三组,每组包括正常体重和肥胖患者:34 名 PCOS 患者、33 名多囊卵巢形态(ECHO 组)的孤立患者和 45 名对照组。通过免疫组织化学、RT-qPCR 和 Western blot 评估卵巢中脂联素和 GRP78 的表达。通过 RT-qPCR 和 ELISA 分别分析颗粒细胞和卵泡液。在体外,用重组人脂联素刺激颗粒细胞,并在存在和不存在针对 GRP78 的 siRNA 的情况下研究其代谢。脂联素在人卵巢中高表达,并通过 GRP78 浓度依赖性地增强颗粒细胞的类固醇生成、增殖和活力(P < 0.0001)。肥胖妇女(P < 0.0001)和正常体重的 ECHO 组(P < 0.001)中颗粒细胞和卵泡液中的脂联素水平均显著升高,GRP78 的表达率也最高(P < 0.05)。尽管需要进一步研究,但脂联素似乎是一种新型的人类颗粒细胞生理学调节剂,可能在 PCOS 发病机制中发挥作用,特别是可保护免受胰岛素抵抗引起的并发症。